2 results
Approved WMOCompleted
To investigate the ability of PF-05089771 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.
Approved WMOCompleted
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.